Mutational Activation of Human ras Genes

  • J. L. Bos


The introduction of new assays for point mutations in chromosomal DNA has enabled us to identify activated ras genes in a large number of human tumors (Table I; ref.1). Thus it became clear that certain tumor types never or only occasionally harbor a mutated ras gene, whereas other tumor types have an activated ras gene more or less frequently (20% to 90% of the cases). On the basis of clinical or histopathological features, a tumor that has a mutated ras gene does not differ from a tumor of the same type that does not. This indicates that the activation of ras is not an essential event. However, since activated ras proteins have cell-transforming properties, and (nearly) all malignant cells of a tumor carry a mutated gene, it is likely that the activation of ras does contribute to the development of tumors. Apparently, other genetic events have similar effects as ras activation.


Acute Myeloid Leukemia Chronic Myeloid Leukemia Mutational Activation Mutagenic Agent Acute Lymphoid Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. L. Bos, Ras gene mutations and human cancer, in: Molecular genetics and the diagnosis of cancer, Elsevier (1989) (Ed. J. Cossman). in press.Google Scholar
  2. 2.
    S. Sukumar, N. Notorio, D. Martin-Zanca, and M. Barbacid, Induction of mammary carcinomas in rats by nitrosomethylurea involves malignant activation of H-ras-1 locus by single point mutations, Nature 306:658 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    M. Quintanilla, R. Brown, M. Ramsden, and A. Balmain, Carcinogenspecific mutation and amplification of Ha-ras during mouse skin carcinogenesis, Nature 322:78 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    K. H. Vousden, and C.J. Marshall, Three different activated ras genes in mouse tumors; evidence for oncogene activation during progression of a mouse lymphoma, EMBO J. 3:913 (1984).PubMedGoogle Scholar
  5. 5.
    B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern, A.C. Preisinger, M. Leppert, Y. Nakamura, R. White, A.M.M. Smits, and J.L. Bos, Genetic alterations during colorectal-tumor development. N.Engl.J Med. 319:525 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    J. W. G. Janssen, A.C.M. Steenvoorden, J. Lyons, B. Anger, J.U. Böhlke, J.L. Bos, H. Seliger, and C.R. Bartram, Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes, Proc.Natl.Acad.Sci. USA 84:9228 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    H. Hirai, M. Okada, H. Mizoguchi, H. Mano, Y. Kobayski, J. Nishida, and F. Takaku, Relationship between activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome, Blood 71:256 (1988).PubMedGoogle Scholar
  8. 8.
    J. J. Yunis, A.J.M. Boot, M.G. Mayer, and J.L. Bos, Preponderance of N-ras mutation in myelodisplastic syndromes with monocytic features and poor prognosis, submitted.Google Scholar
  9. 9.
    A. P. Albino, R. Le Strange, A.I. Oliff, M.E. Furth, and L.J. Old, Transforming ras genes from human melanoma: a manifestation of tumour hetergeneity? Nature 308:69 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    L. J. vant Veer, B.M. Burgering, R. Versteeg „ A.J.M. Boot, D.J. Ruiter, S. Osanto, P.I. Schrier, and J.L. Bos, N-ras mutations in human melanoma, submitted.Google Scholar
  11. 11.
    S. Rodenhuis, R.J.C. Slebos, A.J.M. Boot, S.G. Evers, W.J. Mooi, S.C. Wagenaar, P.Ch. van Bodegom and J.L. Bos, Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung, Cancer Res. 48:5738 (1988).PubMedGoogle Scholar
  12. 12.
    V. T.H.B.M. Smit, A.J.M. Boot, A.M.M. Smits, G.J. Fleuren, C.J. Cornelisse, and J.L. Bos, KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas, Nucl.Acids Res. 16:7773 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • J. L. Bos
    • 1
  1. 1.Laboratory for Molecular CarcinogenesisSylvius LaboratoriesLeidenThe Netherlands

Personalised recommendations